CR20230157A - Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de células falciforme - Google Patents

Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de células falciforme

Info

Publication number
CR20230157A
CR20230157A CR20230157A CR20230157A CR20230157A CR 20230157 A CR20230157 A CR 20230157A CR 20230157 A CR20230157 A CR 20230157A CR 20230157 A CR20230157 A CR 20230157A CR 20230157 A CR20230157 A CR 20230157A
Authority
CR
Costa Rica
Prior art keywords
bis
compounds
modulators
sickle cell
treatment
Prior art date
Application number
CR20230157A
Other languages
English (en)
Inventor
Vu Hong
Zhong Fang
Kevin Guertin
Mark Munson
John Ziqi Jiang
Kunal Desai
Jinyu Liu
Sungtaek Lim
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CR20230157A publication Critical patent/CR20230157A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan en la presente compuestos y composiciones de los mismos para modular la bis-fosfoglicerato mutasa (BPGM) y tratar las células de anemia falciforme.
CR20230157A 2020-09-14 2021-09-14 Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de células falciforme CR20230157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063077973P 2020-09-14 2020-09-14
PCT/US2021/050216 WO2022056449A1 (en) 2020-09-14 2021-09-14 Compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease

Publications (1)

Publication Number Publication Date
CR20230157A true CR20230157A (es) 2023-07-13

Family

ID=78080554

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230157A CR20230157A (es) 2020-09-14 2021-09-14 Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de células falciforme

Country Status (16)

Country Link
US (1) US20230348454A1 (es)
EP (1) EP4210825A1 (es)
JP (1) JP2023541152A (es)
CN (1) CN116406361A (es)
AU (1) AU2021339844A1 (es)
BR (1) BR112023004329A2 (es)
CA (1) CA3194198A1 (es)
CL (1) CL2023000721A1 (es)
CO (1) CO2023003078A2 (es)
CR (1) CR20230157A (es)
DO (1) DOP2023000051A (es)
EC (1) ECSP23019537A (es)
IL (1) IL301169A (es)
MX (1) MX2023003035A (es)
PE (1) PE20240213A1 (es)
WO (1) WO2022056449A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247734B2 (en) * 2001-12-21 2007-07-24 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
GB0524814D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
PE20091953A1 (es) * 2008-05-08 2010-01-09 Du Pont Azoles sustituidos como fungicidas
AU2011326241B2 (en) * 2010-11-09 2016-11-17 Ironwood Pharmaceuticals, Inc. sGC stimulators
WO2018151830A1 (en) * 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
CA3111392A1 (en) * 2018-09-04 2020-03-12 Magenta Therapeutics, Inc. Aryl hydrocarbon receptor antagonists and methods of use

Also Published As

Publication number Publication date
BR112023004329A2 (pt) 2023-04-04
DOP2023000051A (es) 2023-07-16
PE20240213A1 (es) 2024-02-16
AU2021339844A1 (en) 2023-05-04
EP4210825A1 (en) 2023-07-19
CO2023003078A2 (es) 2023-04-27
ECSP23019537A (es) 2023-06-30
WO2022056449A1 (en) 2022-03-17
CL2023000721A1 (es) 2023-10-30
IL301169A (en) 2023-05-01
JP2023541152A (ja) 2023-09-28
AU2021339844A9 (en) 2024-04-18
CN116406361A (zh) 2023-07-07
MX2023003035A (es) 2023-06-06
CA3194198A1 (en) 2022-03-17
US20230348454A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
MX2021013193A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
MX2021013197A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
CR20200545A (es) Inhibidores magl
CO2020010552A2 (es) Compuestos
NZ757081A (en) Somatostatin modulators and uses thereof
MX2022003166A (es) Moduladores de il-17a y usos de los mismos.
MX2022013856A (es) Moduladores htt para tratar la enfermedad de huntington.
EA202191519A1 (ru) Модуляторы trex1
WO2020132661A3 (en) Inhibitors of fibroblast activation protein
MX2023004870A (es) Moduladores de la via integrada del estres.
MX2023008589A (es) Compuestos moduladores de gcn2 y usos de los mismos.
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
ZA202301275B (en) Indole compounds as androgen receptor modulators
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2023005928A (es) Moduladores de malt-1.
CR20230157A (es) Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de células falciforme
MX2022002443A (es) Compuestos inhibidores de perk.
MX2024004416A (es) Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos.
MX2024005884A (es) Usos de compuestos biciclicos para el tratamiento de enfermedades.
CA3155618A1 (en) Treatment of epileptic conditions with gabaa receptor modulators
BR112022011276A2 (pt) Biomolécula para tratamento de patologias da córnea
MX2022005215A (es) Metodos de tratamiento que usan un modulador de la diana mecanicista del complejo 1 de rapamicina (mtorc1).
MX2022000841A (es) Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias.